Clinical trials: Moderate-to-severe Atopic Dermatitis
Moderate to Severe Atopic Dermatitis
Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis
The investigator, the subject, and the sponsor's project team will remain blind throughout the study. Subjects will be randomly assigned to one of the three treatment groups at a ratio of 1:1:1 to be given the drug once a day for…
- Trial name
- NCT05702268
- Testing
- ICP-332
- Where
- 28 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of CM326 in moderate-severe atopic dermatitis subjects.
- Trial name
- NCT05671432
- Testing
- CM326
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate to Severe Atopic Dermatitis
Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis
Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of ISB 830 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT03568162
- Testing
- ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3
- Where
- 83 sites in United States, Canada and 3 more
- Volunteers
- 462 people
- Sponsor
- Ichnos Sciences SA
Moderate-to-severe Atopic Dermatitis
TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
About 60% of all patients with AD are adults. However, the prevalence and incidence is significantly higher in childhood and adolescence.
- Trial name
- TREATgermany (NCT03057860)
- Testing
- No study intervention
- Where
- 3 sites in Germany
- Volunteers
- 2,800 people
- Sponsor
- Technische Universität Dresden
Moderate-to-severe Atopic Dermatitis
Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
This is a multi-center, randomized, double blind, placebo-controlled phase IIb study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in moderate-severe AD subjects.
- Trial name
- NCT04805411
- Testing
- CM310
- Where
- 25 sites in China
- Volunteers
- 120 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate-to-severe Atopic Dermatitis
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.
- Trial name
- NCT05186922
- Testing
- CM326
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate-to-severe Atopic Dermatitis
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of subcutaneously CM310 in moderate-severe AD…
- Trial name
- NCT04893941
- Testing
- CM310
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Keymed Biosciences Co.Ltd
Moderate to Severe Atopic Dermatitis
Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis
The purpose of this study is to determine if twice weekly 10 minute dilute bleach baths decreases disease severity in patients with moderate to severe atopic dermatitis.
- Trial name
- NCT01286220
- Testing
- Dilute bleach baths, Water
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Conditions
- Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic
- Trial name
- NCT03054428
- Testing
- Dupilumab
- Where
- 45 sites in United States, Canada
- Volunteers
- 251 people
- Sponsor
- Regeneron Pharmaceuticals
Moderate to Severe Atopic Dermatitis
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
This is a randomized, double-blind, vehicle-controlled, parallel-group comparison study to evaluate the safety and efficacy of Q301 Cream vs. vehicle in adult subjects with moderate to severe AD.
- Trial name
- NCT02426359
- Testing
- Q301 Cream
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Qurient Co., Ltd.
Moderate/Severe Atopic Dermatitis
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend remission time to relapse and reduce the incidence of disease exacerbation (DE) in paediatric patients over a period of 6 months.
- Trial name
- NCT01745159
- Testing
- tacrolimus
- Where
- 4 sites in China
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma China, Inc.
Moderate to Severe Atopic Eczema
Narrowband UVB for Children With Moderate to Severe Atopic Eczema
To assess prospectively, the response of moderate to severe atopic eczema to a standard course of narrowband ultraviolet B phototherapy by using validated objective and subjective scoring systems.
- Trial name
- NCT01569906
- Testing
- Narrowband Ultraviolet B phototherapy
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- Royal Victoria Infirmary
Moderate to Severe Atopic Dermatitis
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
The study was designed to test the hypothesis whether a standardized, time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe…
- Trial name
- NCT00148746
- Testing
- Pimecrolimus, Tacrolimus, Prednisolone
- Where
- Germany
- Sponsor
- Technische Universität Dresden